NCT07761923Toboroz
Preserving Muscle Mass During Incretin-Induced Weight Loss
Resistance Exercise Training to Preserve Muscle Mass and Physical Function During Incretin-Based Weight Loss
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. nov. 3.
Rövid összefoglaló (regiszter, angolul)
Treatment with incretin-based obesity medications leads to clinically meaningful weight loss and reduced cardiometabolic risk. However, the weight lost includes not only adipose tissue but also skeletal muscle, which may impair physical function and metabolic health. Resistance training is an effective strategy to maintain or increase skeletal muscle mass during weight loss, but its effects during treatment with incretin-based obesity medications have not been studied. This study will investigate whether unilateral resistance training during incretin-based receptor agonist treatment can preserve or improve skeletal muscle volume. The study will also examine whether training affects muscle strength and fatigue tolerance, body composition, cardiac structure and function, and molecular profiles in skeletal muscle, adipose tissue and blood. Participants will be women with obesity who are about to start treatment with an incretin-based receptor agonist as part of routine clinical care. During the 13-week intervention, participants will perform supervised unilateral resistance training twice weekly, training one leg while the other leg serves as an internal control. Assessments before treatment start and after 13 weeks include whole-body and cardiac magnetic resonance imaging, blood sampling, skeletal muscle and adipose tissue biopsies, knee-extensor strength and fatigue tests, and questionnaires. An additional intermediate sampling of blood and tissue (week 4-6) will be collected only in participants who consent to an extra visit.
- Állapot (regiszter)
- Toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 20 (tervezett)
- Első benyújtás
- 2026. júl. 30.
- Kezdés
- 2026. okt. 27.
- Elsődleges befejezés
- 2028. dec. 1.
- Fő szponzor
- Karolinska Institutet
- Betegségek
- Elhízás
- NCT-szám
- NCT07761923
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 20
- 2026. okt. 27. és az elsődleges befejezés (2028. dec. 1.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Previous bariatric surgery.
- The use of medications that cause clinically significant weight gain or loss.
Más betegség
- Medical condition preventing resistance training or physical-function testing.
- Medical condition preventing skeletal muscle or adipose-tissue biopsy.
- Angina pectoris, coronary heart disease or congestive heart failure (NYHA Class III- IV).
- Severe hepatic impairment.
- Inflammatory bowel disease.
- Cancer.
- Chronic obstructive lung disease.
- Severe psychiatric disorders.
- A history of idiopathic acute pancreatitis.
- A family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
- Hypersensitivity to the planned incretin-based medication or any of its excipients.
Laborértékek
- Patients diagnosed with any known serious chronic illness, including type 1 or 2 diabetes (or a randomly measured fasting plasma glucose >7 mmol/L).
- Severe renal impairment (creatinine clearance (GFR) <30 mL/min).
Egyéb
- Contraindication to magnetic resonance imaging.
- A weight reduction >5% during the last 3 months.
- Gastroparesis.
- Osteoarthritis, which is judged to be too severe to manage the exercise programme.
- Pregnancy, expecting pregnancy or breast feeding.
- Regular exercise training at high intensity (eg, spinning) >2 hours per week.
- Inability to understand the study information in Swedish or provide informed consent.
Kiket keres a vizsgálat
- Women aged 18-64 years with obesity, BMI ≥35 kg/m²
- Planned initiation of incretin-based obesity pharmacotherapy as part of routine clinical care.
- Able to participate in supervised unilateral resistance training.
- Able to complete physical function tests.
- Able to attend study visits at the study center.
- Able to provide written informed consent in the Swedish language.
Életkor a regiszterben: 18 év – 64 év · Nem: csak nők · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Karolinska University Hospital Huddinge | Stockholm | Svédország | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.